Insider filing · NVCR

Ashley Cordova bought $997K of NovoCure (NVCR)

Executed Sep 5 2025, disclosed Sep 8 2025, 3 days later.

Over the 21 trading sessions from the disclosed entry session (Sep 8 2025), the stock returned +6.2% (delay-adjusted); from the execution session (Sep 5 2025), +21.5%. Derived: entry at the session's open, exit at the close 20 sessions later.

AC Ashley Cordova Chief Executive Officer profile →

Ashley Cordova (Chief Executive Officer) filed 3 Form 4 reports in the past 24 months (1 purchase, 2 sales), most often in NVCR. Across 1 priced purchase filing, the average 21-session return was +21.5% from execution and +6.2% from disclosure (delay-adjusted; derived). The largest single filing was $997K of NVCR (81,550 sh × $12.22, as filed), executed Sep 5 2025.

NVCR NVCR NVCR · 12 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→